Literature DB >> 8995609

A novel antibody-dependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infection.

O Alsmadi1, R Herz, E Murphy, A Pinter, S A Tilley.   

Abstract

Two monoclonal antibodies (MAbs), 42F and 43F, were isolated some 14 months apart from a single long-term survivor of human immunodeficiency virus type 1 (HIV-1) infection. These MAbs were found to be indistinguishable in terms of their isotypes, specificities, affinities, and biological activities. Both 42F and 43F directed substantial antibody-dependent cellular cytotoxicity (ADCC) against cells infected with four divergent lab-adapted strains of HIV-1, but no neutralizing activity against these strains was detectable. The ability of MAbs 42F and 43F, as well as that of MAbs against two other gp120 epitopes, to direct ADCC against uninfected CD4+ cells to which recombinant gp120SF2 had been adsorbed (i.e., "innocent bystanders") was demonstrated to be less efficient by at least an order of magnitude than their ability to direct ADCC against HIV-1-infected cells. Flow cytometry analyses showed that 42F and 43F also bind to native primary isolate Envs from clades B and E expressed on cell surfaces. By direct binding and competition assays, it was demonstrated that the 42F/43F epitope lies in a domain of gp120 outside the previously described CD4-binding site and V3 loop ADCC epitope clusters. Immunoblot analysis revealed that the 42F/43F epitope is not dependent on disulfide bonds or N-linked glycans in gp120. Epitope mapping of 42F and 43F by binding to linear peptides demonstrated specificity of these MAbs for a sequence of 10 amino acids in the C5 domain comprising residues 491 to 500 (Los Alamos National Laboratory numbering for the HXB2 strain). Thus, 42F and 43F define a new ADCC epitope in gp120. Because of the relative conservation of this epitope and the fact that it appears to have been significantly immunogenic in the individual from which these MAbs were derived, it may prove to be a useful component of HIV vaccines. Furthermore, these MAbs may be used as tools to probe the potential importance of ADCC as an antiviral activity in HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995609      PMCID: PMC191140     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Genetic variants of HIV-1 in Thailand.

Authors:  F E McCutchan; P A Hegerich; T P Brennan; P Phanuphak; P Singharaj; A Jugsudee; P W Berman; A M Gray; A K Fowler; D S Burke
Journal:  AIDS Res Hum Retroviruses       Date:  1992-11       Impact factor: 2.205

2.  A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.

Authors:  A Pinter; W J Honnen; M E Racho; S A Tilley
Journal:  AIDS Res Hum Retroviruses       Date:  1993-10       Impact factor: 2.205

3.  Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.

Authors:  M K Gorny; J Y Xu; S Karwowska; A Buchbinder; S Zolla-Pazner
Journal:  J Immunol       Date:  1993-01-15       Impact factor: 5.422

4.  Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites.

Authors:  A Pinter; W J Honnen; S A Tilley
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

5.  Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.

Authors:  M R Posner; H S Elboim; T Cannon; L Cavacini; T Hideshima
Journal:  AIDS Res Hum Retroviruses       Date:  1992-05       Impact factor: 2.205

6.  The impact of HIV-1 infection on phenotypic and functional parameters of cellular immunity in chimpanzees.

Authors:  G Ferrari; J Ottinger; C Place; S M Nigida; L O Arthur; K J Weinhold
Journal:  AIDS Res Hum Retroviruses       Date:  1993-07       Impact factor: 2.205

7.  Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement.

Authors:  L G Kostrikis; Y Cao; H Ngai; J P Moore; D D Ho
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  Bispecific antibody targeting of human immunodeficiency virus type 1 (HIV-1) glycoprotein 41 to human macrophages through the Fc IgG receptor I mediates neutralizing effects in HIV-1 infection.

Authors:  A Mabondzo; P Aussage; J Bartholeyns; R Le Naour; H Raoul; J L Romet-Lemonne; D Dormont
Journal:  J Infect Dis       Date:  1992-07       Impact factor: 5.226

9.  Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

Authors:  N Sullivan; Y Sun; J Li; W Hofmann; J Sodroski
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

10.  Targeting HIV-1 to Fc gamma R on human phagocytes via bispecific antibodies reduces infectivity of HIV-1 to T cells.

Authors:  A L Howell; P M Guyre; K You; M W Fanger
Journal:  J Leukoc Biol       Date:  1994-03       Impact factor: 4.962

View more
  14 in total

Review 1.  Accessing the human repertoire for broadly neutralizing HIV antibodies.

Authors:  Philip W Hammond
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

2.  Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection.

Authors:  R Ahmad; S T Sindhu; E Toma; R Morisset; J Vincelette; J Menezes; A Ahmad
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

3.  Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection.

Authors:  Derseree Archary; Rong Rong; Michelle L Gordon; Saikat Boliar; Maphuti Madiga; Elin S Gray; Anne-Sophie Dugast; Tandile Hermanus; Philip J R Goulder; Hoosen M Coovadia; Lise Werner; Lynn Morris; Galit Alter; Cynthia A Derdeyn; Thumbi Ndung'u
Journal:  Virology       Date:  2012-09-18       Impact factor: 3.616

4.  Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection.

Authors:  Gamze Isitman; Amy W Chung; Marjon Navis; Stephen J Kent; Ivan Stratov
Journal:  Virology       Date:  2011-01-26       Impact factor: 3.616

5.  Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.

Authors:  O Alsmadi; S A Tilley
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

6.  Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects.

Authors:  Ivan Stratov; Amy Chung; Stephen J Kent
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

7.  A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity.

Authors:  Joshua S Klein; Alexandre Webster; Priyanthi N P Gnanapragasam; Rachel P Galimidi; Pamela J Bjorkman
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

8.  Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development.

Authors:  Gamze Isitman; Ivan Stratov; Stephen J Kent
Journal:  Adv Virol       Date:  2012-04-29

9.  Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.

Authors:  Barbara Falkensammer; Barbara Rubner; Alexander Hiltgartner; Doris Wilflingseder; Christiane Stahl Hennig; Seraphin Kuate; Klaus Uberla; Stephen Norley; Alexander Strasak; Paul Racz; Heribert Stoiber
Journal:  Retrovirology       Date:  2009-06-21       Impact factor: 4.602

10.  Druggable protein interaction sites are more predisposed to surface pocket formation than the rest of the protein surface.

Authors:  David K Johnson; John Karanicolas
Journal:  PLoS Comput Biol       Date:  2013-03-07       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.